Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3079% below fair value
$3.37−0.08 (-2.32%)
Close on Nov 13, 2026Market cap $236.22MP/E –Yield 0.00%
Bicycle Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Bicycle Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -169.8%. For fiscal 2025 it was -301.7%, against -479.2% the year before. The highest annual figure on record is -221.8% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -301.7% | +177.5 |
| FY2024 | Dec 31, 2024 | -479.2% | +190.5 |
| FY2023 | Dec 31, 2023 | -669.7% | +109.6 |
| FY2022 | Dec 31, 2022 | -779.3% | −208.1 |
| FY2021 | Dec 31, 2021 | -571.2% | −80.3 |
| FY2020 | Dec 31, 2020 | -491.0% | −269.2 |
| FY2019 | Dec 31, 2019 | -221.8% | +84.4 |
| FY2018 | Dec 31, 2018 | -306.1% | +483.1 |
| FY2017 | Dec 31, 2017 | -789.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -30.8% | +472.9 |
| Q2 FY2026 | Jun 30, 2026 | -8002.1% | −5298.2 |
| Q1 FY2026 | Mar 31, 2026 | -6857.4% | −6248.4 |
| Q4 FY2025 | Dec 31, 2025 | -42.0% | +1356.4 |
| Q3 FY2025 | Sep 30, 2025 | -503.7% | +1394.8 |
| Q2 FY2025 | Jun 30, 2025 | -2703.8% | −2278.5 |
| Q1 FY2025 | Mar 31, 2025 | -608.9% | −472.9 |
| Q4 FY2024 | Dec 31, 2024 | -1398.4% | −477.4 |
| Q3 FY2024 | Sep 30, 2024 | -1898.4% | −966.1 |
| Q2 FY2024 | Jun 30, 2024 | -425.3% | −51.5 |
| Q1 FY2024 | Mar 31, 2024 | -136.0% | +661.9 |
| Q4 FY2023 | Dec 31, 2023 | -921.0% | +20.2 |
| Q3 FY2023 | Sep 30, 2023 | -932.3% | +0.1 |
| Q2 FY2023 | Jun 30, 2023 | -373.8% | +239.0 |
| Q1 FY2023 | Mar 31, 2023 | -797.9% | −83.8 |
| Q4 FY2022 | Dec 31, 2022 | -941.2% | −462.9 |
| Q3 FY2022 | Sep 30, 2022 | -932.5% | −593.7 |
| Q2 FY2022 | Jun 30, 2022 | -612.8% | +390.7 |
| Q1 FY2022 | Mar 31, 2022 | -714.1% | +181.4 |
| Q4 FY2021 | Dec 31, 2021 | -478.3% | −25.3 |
| Q3 FY2021 | Sep 30, 2021 | -338.7% | −74.9 |
| Q2 FY2021 | Jun 30, 2021 | -1003.5% | −232.4 |
| Q1 FY2021 | Mar 31, 2021 | -895.5% | +107.5 |
| Q4 FY2020 | Dec 31, 2020 | -453.0% | −369.6 |
| Q3 FY2020 | Sep 30, 2020 | -263.9% | +1280.4 |
| Q2 FY2020 | Jun 30, 2020 | -771.2% | −99.9 |
| Q1 FY2020 | Mar 31, 2020 | -1003.0% | −901.1 |
| Q4 FY2019 | Dec 31, 2019 | -83.4% | +544.9 |
| Q3 FY2019 | Sep 30, 2019 | -1544.3% | −1066.5 |
| Q2 FY2019 | Jun 30, 2019 | -671.3% | −371.5 |
| Q1 FY2019 | Mar 31, 2019 | -101.9% | −11.6 |
| Q4 FY2018 | Dec 31, 2018 | -628.3% | – |
| Q3 FY2018 | Sep 30, 2018 | -477.8% | – |
| Q2 FY2018 | Jun 30, 2018 | -299.8% | – |
| Q1 FY2018 | Mar 31, 2018 | -90.2% | – |
See a number that looks wrong?